Evidence mapPaperPMID 41867244Full record

ReviewFrontiers in physiology2026

PANoptosis and mitochondrial regulatory mechanisms in cerebral ischemia-reperfusion injury.

Li Li, Chunyan Guo, Zheng Zuo, Luoyang Cai, Xin Chen, Yongjiang Fang, Shengnan Zhang, Tianyu Chen, Peng Kuang, Pengyue Zhang and 2 more

Abstract readReview
In one paragraph

Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Li Li *Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
Chunyan Guo *The Third Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
Zheng ZuoYunnan University of Chinese Medicine, Kunming, Yunnan, China.
Luoyang CaiYunnan University of Chinese Medicine, Kunming, Yunnan, China.
Xin ChenYunnan University of Chinese Medicine, Kunming, Yunnan, China.
Yongjiang FangThe Third Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
Shengnan ZhangYunnan University of Chinese Medicine, Kunming, Yunnan, China.
Tianyu ChenYunnan University of Chinese Medicine, Kunming, Yunnan, China.
Peng KuangYunnan Cancer Hospital, Kunming, Yunnan, China.
Pengyue ZhangYunnan University of Chinese Medicine, Kunming, Yunnan, China.
Li LiThe Third Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
Zuhong WangThe Third Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral ischemia-reperfusion injury remains a leading cause of mortality and disability despite advances in reperfusion therapy. Traditional research has focused on individual cell death pathways, yet pharmacological blockade of single pathways provides only partial neuroprotection, suggesting that dying cells engage multiple death routes simultaneously. This review examines whether PANoptosis, an inflammatory cell death modality characterized by concurrent activation of apoptotic, necroptotic, and pyroptotic pathways, occurs in cerebral ischemia-reperfusion injury. The analysis demonstrates that mitochondrial dysfunction serves as the central convergence point orchestrating multi-pathway death activation across distinct temporal phases. Ischemia creates metabolic crisis that primes mitochondria without triggering irreversible commitment. Reperfusion causes explosive mitochondrial collapse through oxidative stress, releasing danger signals that simultaneously engage multiple death pathways. Impaired mitochondrial quality control then sustains inflammatory amplification over extended periods. Multiple lines of evidence support this framework, including concurrent rather than sequential appearance of pathway markers, mixed morphological features within individual cells, pathway redundancy demonstrated by incomplete single-target protection, and mechanistic convergence at the mitochondrial level. Cellular responses vary among neurons, astrocytes, microglia, and endothelial cells but share the common feature of coordinated multi-pathway activation. This integrated understanding explains why single-pathway therapeutic approaches have failed clinically and suggests that effective neuroprotection requires targeting upstream mitochondrial dysfunction or addressing pathway redundancy through multi-target interventions.

Indexed as

cell death pathwayscerebral ischemia-reperfusion injurymitochondrial dysfunctionneuroinflammationneuroprotectionPANoptosis

Identifiers

PMID41867244
PMCPMC13003515

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.